Kyverna Therapeutics (NASDAQ:KYTX) Issues Earnings Results, Beats Expectations By $0.03 EPS

Kyverna Therapeutics (NASDAQ:KYTX) posted its quarterly earnings results on Monday. The company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.03, Briefing.com reports.

Kyverna Therapeutics Trading Down 2.0 %

NASDAQ KYTX traded down $0.14 on Wednesday, reaching $6.86. The company had a trading volume of 99,752 shares, compared to its average volume of 520,335. The business has a fifty day moving average price of $9.05. Kyverna Therapeutics has a 52-week low of $6.30 and a 52-week high of $35.06.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on KYTX shares. JPMorgan Chase & Co. lowered their target price on Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. HC Wainwright restated a “neutral” rating and set a $8.00 price objective on shares of Kyverna Therapeutics in a report on Tuesday, July 16th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $34.60.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.